ArticleFrontiers in oncology2025
Visualizing the vascular-cellular microenvironment in lung cancer brain metastasis via multiparametric fusion of DCE-MRI and DWI.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms, Imaging Phenotypes, and Therapeutic Advances of Neovascularization in Brain Metastases.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The heterogeneity of the lung cancer brain metastasis (LCBM) microenvironment limits therapeutic efficacy, while invasive pathological biopsies fail to dynamically assess brain metastasis (BM) comprehensively. Non-invasive imaging techniques thus hold clinical value for visualizing the LCBM microenvironment. This study aimed to achieve non-invasive quantitative analysis of vascular function and cellular structures in LCBM using multiparametric Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) and Diffusion-Weighted Imaging (DWI). Methods: A prospective cohort of 114 LCBM patients (63 lung adenocarcinoma [LUAD]-BM, 28 lung squamous cell carcinoma [LUSC]-BM, 23 small cell lung cancer [SCLC]-BM) underwent DCE-MRI and DWI on a 3.0T MRI scanner. Parameters including volume transfer constant (Ktrans), rate constant (Kep), extravascular extracellular volume (Ve), and plasma volume fraction (Vp) were derived using the Extended Tofts model. Group differences were analyzed via Mann-Whitney U test, diagnostic efficacy via ROC curves, and parameter interactions via multivariate logistic and linear regression. Results: ADC distinguished SCLC-BM from NSCLC-BM with AUC=0.891 (specificity=95.05% at 752.4×10 Conclusion: A DCE-MRI-DWI "Vascular-Cellular Microenvironment Visualization Model" was established, revealing distinct profiles: high microvascular density/permeability in LUAD-BM, low permeability/medium cellularity in LUSC-BM, and high cellularity/abnormal contrast kinetics in SCLC-BM. This validates multimodal imaging for characterizing LCBM heterogeneity and provides insights into tumor angiogenesis, cellular density, and BBB regulation, supporting microenvironment-targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.